➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim
Medtronic
Mallinckrodt
McKinsey

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

JYNARQUE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Jynarque patents expire, and when can generic versions of Jynarque launch?

Jynarque is a drug marketed by Otsuka and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-six patent family members in twenty-four countries.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tolvaptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Jynarque

A generic version of JYNARQUE was approved as tolvaptan by ALKEM LABS LTD on May 19th, 2020.

  Get Started for $10

US Patents and Regulatory Information for JYNARQUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018 RX Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-005 Apr 23, 2018 RX Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-002 Apr 23, 2018 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018 RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JYNARQUE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018   Get Started for $10   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-004 Apr 23, 2018   Get Started for $10   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-004 Apr 23, 2018   Get Started for $10   Get Started for $10
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-003 Apr 23, 2018   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for JYNARQUE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0450097 300408 Netherlands   Get Started for $10 300408, 20101018, EXPIRES: 20151017
0450097 SPC/GB09/037 United Kingdom   Get Started for $10 PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
0450097 C300408 Netherlands   Get Started for $10 PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
0450097 09C0049 France   Get Started for $10 PRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Harvard Business School
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.